Table 2 The registered pharmacotherapy and healthcare utilization during the one-year study period, in total and across the heart failure subgroups
HFrEF | HFmrEF | HFpEF | HFndEF | Total | P-value | |
|---|---|---|---|---|---|---|
Pharmacotherapy | ||||||
RAASi, n (%) | 379 (75) | 346 (73) | 474 (62) | 608 (44) | 1807 (58) | < 0.0011 |
BB, n (%) | 425 (84) | 395 (83) | 534 (70) | 800 (58) | 2154 (69) | < 0.0011 |
MRA, n (%) | 269 (53) | 179 (38) | 233 (31) | 308 (22) | 989 (32) | < 0.0011 |
Diuretics, n (%) | 402 (79) | 358 (76) | 596 (78) | 948 (68) | 2304 (74) | < 0.0011 |
Pharmacotherapy strategies | ||||||
Only diuretics or no HF therapy | 20 (4) | 19 (4) | 74 (10) | 251 (18) | 364 (12) | < 0.0011 |
BB or RAASi | 105 (21) | 109 (23) | 252 (33) | 573 (41) | 1039 (33) | |
BB and RAASi | 357 (70) | 319 (67) | 394 (52) | 516 (37) | 1586 (51) | |
BB, RAASi and MRA | 25 (5) | 27 (6) | 44 (6) | 49 (4) | 145 (5) | |
Healthcare utilization | ||||||
Hospital care | ||||||
Inpatient care (IPC) | ||||||
Hospital admissions, n (SD) | 1.9 (1.4) | 1.7 (1.5) | 1.5 (1.6) | 1.3 (1.3) | 1.5 (1.4) | < 0.0012 |
Hospital days/IPC, n (SD) | 14.4 (13.8) | 11.9 (14.3) | 11.0 (15.1) | 8.8 (11.4) | 10.7 (13.4) | < 0.0012 |
Outpatient care (visits) | ||||||
Physician, n (SD) | 1.6 (2.2) | 1.6 (2.1) | 1.2 (1.8) | 0.5 (1.3) | 1.0 (1.8) | < 0.0012 |
Nurse, n (SD) | 3.0 (6.1) | 1.8 (3.9) | 1.6 (8.1) | 0.6 (4.8) | 1.4 (5.9) | < 0.0012 |
Emergency department, n (SD) | 0.2 (0.6) | 0.2 (0.7) | 0.2 (0.6) | 0.2 (0.5) | 0.2 (0.6) | < 0.0012 |
Primary care | ||||||
Physician (visits), n (SD) | 5.0 (4.8) | 6.3 (5.3) | 6.2 (5.1) | 4.8 (4.9) | 5.4 (5.0) | < 0.0012 |
Nurse (visits), n (SD) | 10.1 (11.9) | 11.2 (13.2) | 10.3 (13.2) | 6.5 (10.1) | 8.7 (11.9) | < 0.0012 |